간신증후군 시장 규모, 점유율, 성장 분석 : 질환별, 치료법별, 약물 계열별, 투여 경로별, 최종사용자별, 유통 채널별, 지역별 - 업계 예측(2026-2033년)

Global Hepatorenal Syndrome Market size was valued at USD 1.3 Billion in 2024 and is poised to grow from USD 1.39 Billion in 2025 to USD 2.42 Billion by 2033, growing at a CAGR of 7.1% during the forecast period (2026-2033).

The hepatorenal syndrome market encompasses diagnostics, therapeutics, and supportive care for individuals experiencing simultaneous liver failure and kidney dysfunction, a condition associated with over 70% mortality and significant intensive-care admissions globally. Growth in this sector is primarily driven by the increasing incidence of chronic liver diseases, such as alcohol-related cirrhosis and non-alcoholic steatohepatitis, alongside rising events of acute kidney injury. Regulatory approvals for HRS therapies are expediting market entry, leading companies to create bundled treatment options that combine terlipressin and albumin for outpatient dialysis utilization. Evidence from healthcare facilities indicates a notable reduction in liver transplant demands with these treatment regimens, resulting in cost efficiencies for insurers. Additionally, the high prevalence of hepatitis B-related cirrhosis in certain regions fuels market opportunities for multinational corporations to establish local operations and conduct clinical trials.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Hepatorenal Syndrome market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Hepatorenal Syndrome Market Segments Analysis

Global hepatorenal syndrome market is segmented by disease type, treatment type, drug class, route of administration, end user, distribution channel and region. Based on disease type, the market is segmented into Type 1 Hepatorenal Syndrome (HRS-AKI) and Type 2 Hepatorenal Syndrome (HRS-NAKI). Based on treatment type, the market is segmented into Vasoconstrictor Therapy, Albumin Therapy, Renal Replacement Therapy (Dialysis), Liver Transplantation and Others. Based on drug class, the market is segmented into Terlipressin, Norepinephrine, Midodrine + Octreotide, Albumin and Others. Based on route of administration, the market is segmented into Intravenous, Oral and Subcutaneous. Based on end user, the market is segmented into Hospitals, Specialty Liver Centers, Ambulatory Care Centers and Transplant Centers. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Specialty Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Hepatorenal Syndrome Market

The increasing prevalence of chronic liver diseases, including cirrhosis and hepatitis B, contributes to a larger population susceptible to hepatorenal syndrome. This rise in at-risk patients intensifies the need for therapeutic solutions, clinical monitoring tools, and supportive care services. As healthcare systems allocate more resources to address these complications, pharmaceutical and diagnostic companies are motivated to expand their product offerings. This dynamic fosters continuous growth in the market, as healthcare professionals pursue effective strategies to prevent renal decline in individuals suffering from liver-related conditions. Ultimately, the push for improved patient care drives innovation and investment in this sector.

Restraints in the Global Hepatorenal Syndrome Market

The high cost of approved medications for hepatorenal syndrome presents a considerable challenge for both healthcare providers and patients, especially in areas where reimbursement options are scarce. These elevated prices often discourage the inclusion of these therapies in formularies, prompting healthcare professionals to favor more affordable supportive treatments instead of investing in costly targeted options. This price sensitivity limits market penetration and slows the rate at which new therapies are adopted, as institutions strive to find economical ways to operate within their constrained budgets. As a result, the growth of the market is significantly restricted by these economic hurdles, which impede access to innovative treatment solutions.

Market Trends of the Global Hepatorenal Syndrome Market

The Global Hepatorenal Syndrome market is experiencing a significant trend toward precision medicine, characterized by the integration of specific molecular biomarkers that distinguish between subtypes of the syndrome. This advancement facilitates earlier and more tailored clinical interventions, reducing the need for invasive diagnostic procedures and expediting treatment decisions. The increasing adoption of multiplex testing platforms is empowering healthcare professionals with actionable insights that enhance patient stratification for clinical trials. This trend is fostering greater collaboration between nephrologists and hepatologists while promoting the implementation of targeted therapeutic protocols, ultimately reshaping the treatment landscape and improving outcomes for patients worldwide.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Hepatorenal Syndrome Market Size by Disease Type & CAGR (2026-2033)

• Market Overview
• Type 1 Hepatorenal Syndrome (HRS-AKI)
• Type 2 Hepatorenal Syndrome (HRS-NAKI)

Global Hepatorenal Syndrome Market Size by Treatment Type & CAGR (2026-2033)

• Market Overview
• Vasoconstrictor Therapy
• Albumin Therapy
• Renal Replacement Therapy (Dialysis)
• Liver Transplantation
• Others

Global Hepatorenal Syndrome Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• Terlipressin
• Norepinephrine
• Midodrine + Octreotide
• Albumin
• Others

Global Hepatorenal Syndrome Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Intravenous
• Oral
• Subcutaneous

Global Hepatorenal Syndrome Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Specialty Liver Centers
• Ambulatory Care Centers
• Transplant Centers

Global Hepatorenal Syndrome Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Specialty Pharmacies

Global Hepatorenal Syndrome Market Size & CAGR (2026-2033)

• North America (Disease Type, Treatment Type, Drug Class, Route of Administration, End User, Distribution Channel)
  • US
  • Canada
• Europe (Disease Type, Treatment Type, Drug Class, Route of Administration, End User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Disease Type, Treatment Type, Drug Class, Route of Administration, End User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Disease Type, Treatment Type, Drug Class, Route of Administration, End User, Distribution Channel)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Disease Type, Treatment Type, Drug Class, Route of Administration, End User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Mallinckrodt Pharmaceuticals plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Baxter International Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Grifols, S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CSL Behring LLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fresenius Medical Care AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ferring Pharmaceuticals A/S
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Octapharma AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pharmazz, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nikkiso Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Terumo Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kedrion S.p.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Innoviva Specialty Therapeutics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ocelot Bio, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cumberland Pharmaceuticals Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SeaStar Medical Holding Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Lifesciences Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations